{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(8)"],"submitter":["Bagchi S"],"pubmed_abstract":["<h4>Introduction</h4>IgA nephropathy (IgAN) is the most common primary glomerular disease in adults. In recent years, there have been many significant advances in treating IgAN, with multiple successful clinical trials. We aim to determine the comparative effectiveness of available pharmaceutical interventions for treating IgAN.<h4>Methods and analysis</h4>A systematic review and network meta-analysis (NMA) will be conducted to assess the comparative effectiveness and safety of various pharmacological interventions available for adults with IgAN. All randomised controlled trials (RCTs) or quasi-RCTs which have evaluated pharmacological interventions in IgAN will be included. Both published studies and those available only as conference abstracts will be considered. A systematic literature "],"journal":["BMJ open"],"pagination":["e106553"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12410667"],"repository":["biostudies-literature"],"pubmed_title":["Pharmacological interventions in IgA nephropathy: protocol for a living systematic review and network meta-analysis."],"pmcid":["PMC12410667"],"pubmed_authors":["Strippoli G","Tunnicliffe D","Guha C","Chung E","Saleem N","Teixeira-Pinto A","Scholes-Robertson NJ","Natale P","Kieu A","Wong G","Bagchi S"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacological interventions in IgA nephropathy: protocol for a living systematic review and network meta-analysis.","description":"<h4>Introduction</h4>IgA nephropathy (IgAN) is the most common primary glomerular disease in adults. In recent years, there have been many significant advances in treating IgAN, with multiple successful clinical trials. We aim to determine the comparative effectiveness of available pharmaceutical interventions for treating IgAN.<h4>Methods and analysis</h4>A systematic review and network meta-analysis (NMA) will be conducted to assess the comparative effectiveness and safety of various pharmacological interventions available for adults with IgAN. All randomised controlled trials (RCTs) or quasi-RCTs which have evaluated pharmacological interventions in IgAN will be included. Both published studies and those available only as conference abstracts will be considered. A systematic literature ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-05-29T21:15:03.623Z","creation":"2026-04-08T06:01:09.827Z"},"accession":"S-EPMC12410667","cross_references":{"pubmed":["40866062"],"doi":["10.1136/bmjopen-2025-106553"]}}